- Home
- AMRN
as 07-26-2024 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Upcoming Earnings Alert:
Get ready for potential market movements as Amarin Corporation plc AMRN prepares to release earnings report on 31 Jul 2024.
| Founded: | N/A | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 355.4M | IPO Year: | 1993 |
| Target Price: | $1.08 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $1.37 | Next Earning Date: | 07-31-2024 |
| Revenue: | $277,455,000 | Revenue Growth: | -23.04% |
| Revenue Growth (this year): | -32.83% | Revenue Growth (next year): | 3.17% |
Stock Insider Trading Activity of Amarin Corporation plc (AMRN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Holt Patrick | AMRN | President and CEO | Jan 22 '24 | Buy | $1.09 | 14,426 | $15,724.34 | 314,426 | SEC Form 4 |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Simply Wall St.
4 days ago
Amarin Corporation plc's (NASDAQ:AMRN) Intrinsic Value Is Potentially 29% Above Its Share Price
MT Newswires
8 days ago
Sector Update: Health Care Stocks Edge Lower Premarket Thursday
MT Newswires
9 days ago
Amarin Says Vazkepa Secures National Reimbursement in Portugal
GlobeNewswire
9 days ago
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
GlobeNewswire
10 days ago
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
MT Newswires
19 days ago
Amarin Commercial Partner in China Receives Regulatory Approval for Heart Drug Vascepa
GlobeNewswire
19 days ago
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.